| Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma (NCT06309459) | Kahramanmaras Sutcu Imam University | 2018-08-01 |
| Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (NCT03243838) | Guangdong Provincial People's Hospital | 2018-08-01 |
| A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients (NCT03671044) | Jina Pharmaceuticals Inc. | 2018-07-10 |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer (NCT03499899) | Novartis Pharmaceuticals | 2018-07-02 |
| CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) (NCT03504488) | BioAtla, Inc. | 2018-06-27 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer (NCT03920488) | European Institute of Oncology | 2018-06-01 |
| OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease (NCT03487666) | Georgetown University | 2018-05-21 |
| Ribociclib and Bicalutamide in AR+ TNBC (NCT03090165) | Kari Wisinski | 2018-05-07 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (NCT03475953) | Institut Bergonié | 2018-05-04 |
| Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer (NCT03473691) | University of Virginia | 2018-05-01 |
| GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors (NCT03576131) | Genmab | 2018-04-30 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCT03449108) | M.D. Anderson Cancer Center | 2018-04-27 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (NCT03387085) | ImmunityBio, Inc. | 2018-03-19 |
| REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies (NCT03435640) | Nektar Therapeutics | 2018-03-15 |
| Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer (NCT03358017) | Mario Negri Institute for Pharmacological Research | 2018-03-05 |
| Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer (NCT03457779) | Baylor Research Institute | 2018-02-08 |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) (NCT03401385) | Daiichi Sankyo Co., Ltd. | 2018-01-31 |
| Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. (NCT03197389) | Universitaire Ziekenhuizen KU Leuven | 2018-01-18 |
| ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma (NCT03394027) | National Cancer Institute (NCI) | 2018-01-17 |
| A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients (NCT03145961) | Institute of Cancer Research, United Kingdom | 2017-12-21 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (NCT03289962) | Genentech, Inc. | 2017-12-21 |
| Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo (NCT03281954) | NSABP Foundation Inc | 2017-12-19 |
| PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (NCT03362060) | Massachusetts General Hospital | 2017-12-12 |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (NCT03251378) | Hutchison Medipharma Limited | 2017-12-11 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (NCT03175666) | ImmunityBio, Inc. | 2017-12-01 |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors (NCT03343613) | Eli Lilly and Company | 2017-11-17 |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (NCT03292172) | Hoffmann-La Roche | 2017-11-08 |
| Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer (NCT03301350) | University of Wisconsin, Madison | 2017-11-07 |
| Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (NCT02977468) | Eileen Connolly | 2017-10-25 |
| Comparison of the Breast Tumor Microenvironment (NCT03165487) | Columbia University | 2017-09-28 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (NCT03267316) | Cantargia AB | 2017-09-19 |
| Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer (NCT03348098) | Tianjin Medical University Cancer Institute and Hospital | 2017-09-06 |
| Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer (NCT03206203) | Vanderbilt-Ingram Cancer Center | 2017-08-29 |
| Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer (NCT03586297) | Hackensack Meridian Health | 2017-08-27 |
| A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (NCT03125902) | Hoffmann-La Roche | 2017-08-25 |
| A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer (NCT03186937) | University of Wisconsin, Madison | 2017-08-10 |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC (NCT03184558) | BerGenBio ASA | 2017-07-26 |
| Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy (NCT03750240) | NYU Langone Health | 2017-07-25 |
| A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (NCT03197935) | Hoffmann-La Roche | 2017-07-24 |
| TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer (NCT03193853) | Joyce O'Shaughnessy | 2017-07-18 |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment (NCT03358004) | Mario Negri Institute for Pharmacological Research | 2017-06-14 |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) (NCT03057600) | Calithera Biosciences, Inc | 2017-05-01 |
| Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (NCT03356860) | Grand Hôpital de Charleroi | 2017-04-13 |
| Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer (NCT02984683) | Sanofi | 2017-03-23 |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients (NCT03075462) | Jiangsu HengRui Medicine Co., Ltd. | 2017-03-09 |
| Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer (NCT03244358) | Sun Yat-sen University | 2017-03-01 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer (NCT02981303) | HiberCell, Inc. | 2017-02-22 |
| Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) (NCT02950259) | Providence Health & Services | 2017-02-09 |
| A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy (NCT04297267) | Fudan University | 2017-02-07 |
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) (NCT02978716) | G1 Therapeutics, Inc. | 2017-02-02 |
| AVID100 in Advanced Epithelial Carcinomas (NCT03094169) | Formation Biologics | 2017-02-01 |
| Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (NCT03017573) | Institut Curie | 2017-01-06 |
| Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer (NCT01676753) | Jo Chien | 2016-12-28 |
| Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (NCT03333915) | BeiGene | 2016-12-21 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (NCT02983045) | Nektar Therapeutics | 2016-12-19 |
| A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer (NCT03002103) | SynCore Biotechnology Co., Ltd. | 2016-11-23 |
| A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02936102) | Novartis Pharmaceuticals | 2016-10-20 |
| Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer (NCT02768701) | UNC Lineberger Comprehensive Cancer Center | 2016-10-18 |
| Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer (NCT02685657) | Russian Academy of Medical Sciences | 2016-09-01 |
| DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (NCT03154749) | Guangdong Provincial People's Hospital | 2016-09-01 |
| Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer (NCT02161679) | Gilead Sciences | 2016-08-01 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (NCT02807844) | Novartis Pharmaceuticals | 2016-06-29 |
| Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer (NCT02750358) | Memorial Sloan Kettering Cancer Center | 2016-05-19 |
| A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (NCT02632448) | Esperas Pharma Inc. | 2016-05-16 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (NCT02657889) | Tesaro, Inc. | 2016-04-15 |
| Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (NCT02644369) | University Health Network, Toronto | 2016-03-21 |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer (NCT02685306) | Peregrine Pharmaceuticals | 2016-03-01 |
| Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer (NCT02734290) | Providence Health & Services | 2016-02-23 |
| TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature (NCT02641847) | Fudan University | 2016-01-01 |
| Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients (NCT02681562) | Istituti Ospitalieri di Cremona | 2016-01-01 |
| A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation. (NCT02639832) | Cynvenio Biosystems | 2015-12-01 |
| Emotions Immunology and Breast Cancer (NCT03609671) | Luz A. Venta, MD | 2015-11-23 |
| Study of Tremelimumab in Patients With Advanced Solid Tumors (NCT02527434) | AstraZeneca | 2015-11-02 |
| Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers (NCT02616848) | Istituti Ospitalieri di Cremona | 2015-11-01 |
| Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso (NCT02580747) | Chinese PLA General Hospital | 2015-10-01 |
| Huaier Granule in Treating Women With Triple Negative Breast Cancer (NCT02615457) | Shandong University | 2015-10-01 |
| A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer (NCT02543645) | Celldex Therapeutics | 2015-10-01 |
| Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer (NCT02595138) | Chinese Academy of Medical Sciences | 2015-10-01 |
| Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy (NCT02427581) | Washington University School of Medicine | 2015-09-29 |
| Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors (NCT02401347) | Melinda Telli | 2015-08-01 |
| Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib (NCT02511847) | National Taiwan University Hospital | 2015-08-01 |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) (NCT02580448) | Innocrin Pharmaceutical | 2015-08-01 |
| Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (NCT02393794) | Priyanka Sharma | 2015-07-17 |
| A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) (NCT02425891) | Hoffmann-La Roche | 2015-06-23 |
| Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy (NCT02348320) | Washington University School of Medicine | 2015-06-17 |
| Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) (NCT02368691) | GTx | 2015-06-01 |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (NCT02583542) | Queen Mary University of London | 2015-06-01 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies (NCT02404441) | Novartis Pharmaceuticals | 2015-04-27 |
| PCA062 in pCAD-positive Tumors. (NCT02375958) | Novartis Pharmaceuticals | 2015-04-15 |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (NCT02315196) | Rutgers, The State University of New Jersey | 2015-02-25 |
| A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (NCT02365662) | AbbVie | 2015-01-09 |
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors (NCT02307240) | Curis, Inc. | 2014-11-01 |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-23 |
| Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer (NCT02247037) | Icahn School of Medicine at Mount Sinai | 2014-07-01 |
| MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer (NCT01805076) | Alliance for Clinical Trials in Oncology | 2014-05-21 |
| A Study Of PF-06647263 In Patients With Advanced Solid Tumors (NCT02078752) | Pfizer | 2014-04-09 |